PLPPR1 Gene

PLPPR1 — Phospholipid Phosphatase-Related Protein 1

Overview

PLPPR1 (Phospholipid Phosphatase-Related Protein 1), also known as PLPPR1 or LPR1, is a member of the lipid phosphate phosphatase (LPP) family within the broader family of phosphatidic acid phosphatases (PAPs). PLPPR1 dephosphorylates bioactive lipid phosphates including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), which are critical signaling molecules in the nervous system[@plppr2023]. PLPPR1 plays essential roles in neuronal development, synaptic plasticity, and neuroinflammation, and emerging evidence suggests it may be implicated in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@lysophosphatidic2022].

The lipid phosphate phosphatase family consists of six members (PLPPR1-5 and LPP) that share conserved catalytic domains but exhibit distinct tissue expression patterns and substrate specificities[@lipid2024]. PLPPR1 is particularly enriched in the nervous system, where it modulates lipid signaling pathways that control neuronal viability, synaptic function, and inflammatory responses.

Gene Information

PLPPR1 — Phospholipid Phosphatase-Related Protein 1

Overview

PLPPR1 (Phospholipid Phosphatase-Related Protein 1), also known as PLPPR1 or LPR1, is a member of the lipid phosphate phosphatase (LPP) family within the broader family of phosphatidic acid phosphatases (PAPs). PLPPR1 dephosphorylates bioactive lipid phosphates including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), which are critical signaling molecules in the nervous system[@plppr2023]. PLPPR1 plays essential roles in neuronal development, synaptic plasticity, and neuroinflammation, and emerging evidence suggests it may be implicated in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@lysophosphatidic2022].

The lipid phosphate phosphatase family consists of six members (PLPPR1-5 and LPP) that share conserved catalytic domains but exhibit distinct tissue expression patterns and substrate specificities[@lipid2024]. PLPPR1 is particularly enriched in the nervous system, where it modulates lipid signaling pathways that control neuronal viability, synaptic function, and inflammatory responses.

Gene Information

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PLPPR1 Gene Summary</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>PLPPR1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Phospholipid Phosphatase-Related Protein 1</td></tr>
<tr><td><strong>Aliases</strong></td><td>LPR1, PAP2, LPP1</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>9p13.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[23016](https://www.ncbi.nlm.nih.gov/gene/23016)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000143125</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y329](https://www.uniprot.org/uniprot/Q9Y329)</td></tr>
<tr><td><strong>Gene Type</strong></td><td>Protein coding</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Schizophrenia, Bipolar Disorder</td></tr>
</table>
</div>

Protein Structure and Catalytic Mechanism

Domain Architecture

PLPPR1 is a type II transmembrane protein with a distinctive domain organization:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal transmembrane domain | 1-50 aa | Membrane anchoring |
| Extracellular/luminal domain | 51-300 aa | Catalytic phosphatase domain |
| C-terminal cytoplasmic tail | 301-360 aa | Intracellular signaling |

Catalytic Activity

PLPPR1 belongs to the haloacid dehalogenase (HAD) superfamily of hydrolases[@lpp structure]. The catalytic mechanism involves:

Substrate Specificity

PLPPR1 demonstrates differential activity toward its substrate pool[@lipid2024]:

| Substrate | Catalytic Efficiency | Biological Significance |
|-----------|---------------------|----------------------|
| Lysophosphatidic acid (LPA) | High | Primary substrate |
| Sphingosine-1-phosphate (S1P) | Moderate | Alternative substrate |
| Diacylglycerol pyrophosphate | Low | Minor substrate |
| Ceramide-1-phosphate | Low | Minor substrate |

Physiological Functions

Lipid Signaling Modulation

PLPPR1 functions as a key regulator of bioactive lipid signaling by controlling extracellular and intracellular concentrations of LPA and S1P[@lpa receptors]:

• LPA regulation: Dephosphorylates LPA to monoacylglycerol (MAG), terminating LPA signaling
• S1P regulation: Modulates S1P levels, affecting cell survival and migration
• Spatial signaling: Shapes lipid gradients important for cell-cell communication

Neuronal Development

During brain development, PLPPR1 plays critical roles[@lpa neurodevelopment]:

Synaptic Plasticity

PLPPR1 modulates synaptic function through lipid signaling pathways[@synapse plasticity]:

• LTP regulation: LPA receptor activation affects long-term potentiation
• LTD regulation: Controls AMPA receptor internalization
• Presynaptic function: Modulates neurotransmitter release
• Postsynaptic density: Influences dendritic spine morphology

Expression Pattern

PLPPR1 exhibits cell-type specific expression throughout the nervous system[@plppr expression]:

Neuronal Expression

• Cortical neurons: High expression in layers II-IV pyramidal neurons
• Hippocampal neurons: Strong expression in CA1 pyramidal cells and granule cells
• Cerebellar Purkinje cells: High expression in postsynaptic dendrites
• Dopaminergic neurons: Moderate expression in substantia nigra pars compacta

Glial Expression

• Oligodendrocytes: Moderate to high expression, highest in pre-myelinating stages
• Astrocytes: Low to moderate expression, increases in reactive astrocytes
• Microglia: Low basal expression, increases upon activation

Role in Neurodegenerative Diseases

Alzheimer's Disease

PLPPR1 is implicated in multiple aspects of AD pathogenesis[@lysophosphatidic2022][@ad lipid dysregulation]:

Amyloid-beta metabolism:

• LPA signaling enhances Aβ production through γ-secretase modulation
• PLPPR1 activity may reduce LPA-mediated Aβ toxicity
• Altered PLPPR1 expression in AD brain may contribute to pathogenesis

• LPA can activate kinases involved in tau phosphorylation
• PLPPR1 may indirectly modulate tau pathology through lipid signaling

• LPA acts as pro-inflammatory mediator in microglia[@lpa inflammation]
• PLPPR1 may regulate microglial activation states

• LPA impairs synaptic plasticity and memory formation
• PLPPR1 protects against LPA-mediated synaptic deficits

• PLPPR1 variants have been associated with AD risk in some populations
• Expression quantitative trait loci (eQTLs) in AD brain tissue

Parkinson's Disease

In PD, PLPPR1 may play protective roles in dopaminergic neurons[@pd lipid metabolism][@dopamine lpa]:

Multiple Sclerosis

PLPPR1 intersects with S1P signaling, a major pathway in MS therapy[@ms therapy]:

• Oligodendrocyte function: PLPPR1 may influence myelination/remyelination
• Immune cell trafficking: S1P gradients control lymphocyte egress
• Neuroprotection: S1P has pro-survival effects in CNS cells

Psychiatric Disorders

PLPPR1 genetic variants have been associated with neuropsychiatric conditions[@plppr2023a]:

• Schizophrenia: GWAS signals near PLPPR1 locus
• Bipolar disorder: Rare variant associations reported
• Depression: Expression changes in postmortem brain

Signaling Pathways

LPA Receptor Signaling

LPA signals through six G protein-coupled receptors (LPA1-6)[@lpa receptors][@lpa g-protein]:

S1P Receptor Signaling

S1P signals through five receptors (S1PR1-5)[@s1p signaling]:

• S1PR1: Gi-coupled, promotes cell survival via Akt
• S1PR2: Gq-coupled, modulates calcium
• S1PR3: Gi/Gq-coupled, multiple effects
• S1PR4/5: Hematopoietic and neuronal functions

Cross-Talk Between Pathways

PLPPR1 sits at the intersection of multiple lipid signaling networks:

| Pathway | Interaction | Functional Outcome |
|---------|-------------|--------------------|
| LPA/S1P | Shared substrates | Competitive regulation |
| PI3K/Akt | Downstream of both | Cell survival modulation |
| MAPK | Both can activate | Growth/differentiation |
| Rho GTPases | LPA-mediated | Cytoskeletal dynamics |

Therapeutic Implications

Targeting LPA Signaling

Since PLPPR1 modulates LPA levels, therapeutic strategies include[@lpa receptors]:

Targeting S1P Signaling

S1P receptor modulators are already used in MS[@ms therapy]:

• Fingolimod (Gilenya): S1PR1 modulator, approved for MS
• Siponimod (Mayzent): S1PR1/5 modulator
• Ozanimod: S1PR1/5 modulator
• Ponesimod: S1PR1 modulator

Challenges and Opportunities

| Challenge | Opportunity |
|-----------|-------------|
| Blood-brain barrier penetration | Brain-penetrant LPA antagonists |
| Receptor subtype selectivity | Selective S1P modulators |
| PLPPR1 targeting | Small molecule activators |
| Biomarker development | Patient stratification markers |

Genetic Studies

GWAS Associations

PLPPR1 genetic variants have been examined in neurodegenerative diseases[@plppr2023a]:

• Alzheimer's disease: Inconsistent associations across populations
• Parkinson's disease: Limited evidence for rare variants
• Schizophrenia: Some GWAS signals near PLPPR1 locus
• Bipolar disorder: Rare variant associations reported

Expression Studies

• AD brain: Altered PLPPR1 expression in prefrontal cortex
• PD brain: Changes in substantia nigra
• MS lesions: PLPPR1 in demyelinating plaques

Research Models

Animal Models

| Model | Utility | Limitations |
|-------|---------|-------------|
| PLPPR1 knockout mice | Developmental studies | Viable, mild phenotype |
| Conditional knockouts | Cell-type specific functions | Limited availability |
| Transgenic overexpression | Disease modeling | Potential artifacts |
| Humanized mice | Drug testing | Cost |

Cell Culture Models

• Primary neurons: Mouse/rat cortical and hippocampal neurons
• iPSC-derived neurons: Patient-specific disease modeling
• Organoids: 3D brain models

Biomarker Potential

Diagnostic Markers

• PLPPR1 expression in peripheral blood mononuclear cells
• LPA/S1P ratio in cerebrospinal fluid
• Genetic variants as risk biomarkers

Prognostic Markers

• Disease progression correlates
• Treatment response prediction

See Also

• [Lipid Signaling in Neurodegeneration](/mechanisms/lipid-signaling-neurodegeneration)
• [Sphingolipid Metabolism](/mechanisms/sphingolipid-metabolism-neurodegeneration)
• [LPA Signaling Pathway](/mechanisms/lpa-signaling-neurodegeneration)
• [S1P Signaling Pathway](/mechanisms/s1p-signaling-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [PLP1 Gene](/genes/plp1)
• [PLP2 Gene](/genes/plp2)

External Links

• [NCBI Gene: PLPPR1](https://www.ncbi.nlm.nih.gov/gene/23016)
• [UniProt: Q9Y329](https://www.uniprot.org/uniprot/Q9Y329)
• [AlphaFold Structure](https://alphafold.ebi.ac.uk/entry/Q9Y329)
• [KEGG Pathway: Sphingolipid signaling](https://www.genome.jp/kegg/pathway.html)

Key Publications

References